Mr. Michael Frank reports
REVIVE THERAPEUTICS PARTNERS WITH SUPRIYA TO PURSUE EUA FOR BUCILLAMINE TO TREAT COVID IN INDIA
Revive Therapeutics Ltd. has entered into a memorandum of understanding dated June 7, 2021, with Supriya Lifescience Ltd., a specialty pharmaceutical company based in India, to pursue manufacturing of the API, conducting clinical registration and commercialization for bucillamine to treat COVID-19 through emergency-use authorization (EUA) in India. The relationship also sets the foundation for Revive to expand commercialization efforts globally by leveraging Supriya's extensive manufacturing and commercial network and Revive's continuing U.S. FDA phase 3 clinical study results of bucillamine to treat mild-to-moderate COVID-19.
"While our phase 3 clinical study for COVID-19 is ongoing in the USA, we are laying the ground work by partnering with Supriya to execute on our global manufacturing and commercialization plans and leveraging their regulatory expertise and commercial reach with 78 countries they currently supply pharmaceutical products to," said Michael Frank, chief executive officer of Revive. "We are focused on completing our current phase 3 study in the USA and also obtaining EUA. These results will support drug approval registrations globally, including India, Europe and Canada."
Dr. Satish Wagh, CMD, Supriya Lifescience, said: "Through this collaboration, we aim to join our forces with Revive to accelerate access to bucillamine in India at a time when it is most needed. This is a step towards making more treatment options available to patients in India in dealing with the pandemic. With this partnership, Supriya aims to enter into a niche area of chemistry and products thereby bolstering its CMO and research capabilities."
The company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 coronavirus) at this time.
About Revive Therapeutics Ltd.
Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as orphan drug, fast track, breakthrough therapy and rare pediatric disease designations. Currently, the company is exploring the use of bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of psilocybin-based therapeutics in various diseases and disorders. Revive's cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases, and the company was granted FDA orphan drug status designation for the use of cannabidiol (CBD) to treat autoimmune hepatitis (liver disease), and to treat ischemia and reperfusion injury from organ transplantation.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.